University of Kentucky Research Foundation

Bioventures, LLC

Targacept, Inc.

Other

University of Colorado

University of Arkansas

Ceptaris Therapeutics, Inc.

University of Utah Research Foundation

University of Rochester

The United States Government as Represented by the Department of Veterans Affairs

Actelion Pharmaceuticals Ltd

Mitochon Pharmaceuticals, Inc.

Cornell University

Vanderbilt University

Southern Research Institute

Peter Anthony Crooks

Linda P Dwoskin

Craig T Jordan

Narsimha Reddy Penthala

Gary Maurice Dull

Guangrong Zheng

William Scott Caldwell

Balwinder Singh Bhatti

Robert Alonso

Sangeetha Sumithran

Haeil Park

Xiaochen Wei

Jared Miller Wagner

Mark A Pimley

Venumadhav Janganati

Srishailkumar Basawannappa Hadimani

Shobanbabu Bommagani

Niranjan Madhukar Deo

Joseph R Holtman

Jessica Ponder

Paul Ashton

Tadeusz Cynkowski

Grazyna Cynkowska

Zhenfa Zhang

Alain Ravard

J Michael McIntosh

Merouane Bencherif

Patrick Michael Lippiello

Roger Lee Papke

David R Worthen

Vladimir P Grinevich

Marlon D Jones

Rui Xu

Audra Lynn Stinchcomb

Cesar M Compadre

Hong Guo

John Gerard Geisler

Abeer M Al-Ghananeem

Nikhil Reddy Madadi

Leena Maddukuri

Robert Eoff

Dennis Keith Miller

Elzbieta Pogonowska Wala

Zaineb Albayati

Joshua T Ayers

Paul Lockman

Vijayakumar Sonar

Mohamed Omer Hamad

Soma Shekar Dachavaram

Gerald A Rosenthal

Zhenfa Zheng

John P Moore

Ujjwal Chakraborty

Marharyta Pivavarchyk

John A Montgomery

Martin Stogniew

John A Secrist, Iii

Stefan Kwiatkowski

Jeffrey Daniel Schmitt

Jon Scott Thorson

Joseph A Maddry

David S Watt

Jamie Allen Hestekin

Philip J Breen

Robert C Reynolds

Jared T Hammill

Martin Hauer-Jensen

Darin E Jones

Thirupathi Reddy Yerramreddy

Clair L Hicks

Abdulghani A Houdi

Thomas J Smith

Monica L Guzman

Omar Malagon

Shraddha Thakkar

Paola E Ordonez

Jawahar L Mehta

Srishakumar Basawannappa Hadimani

Ashish Pramod Vartak

Aimee K Bence

Seth Davin Norholm

Sairam Krishamurthy

Aimee Karis Bence

David Robert Worthern

Linda Dwoshin

David Allen

Magomed Khaidakov

Kottayil I Varughese

Justin R Nickell

Yao Dai

Zheng Cao

Seth Davin Norrholm

Na-Ra Lee

Santosh G Kottayil

D Allen Butterfield

Omar A Ghosheh

Hone Guo

Shanshan Pei

Shama Nasim

Giovanni Vidari

A cellulose based anti-viral/anti-microbial coating.

Cellulose based anti-viral anti-microbial spray coating

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse

In one aspect, TEMPO-cellulose structures and method of making the same are described herein. Briefly, a method of synthesizing TEMPO-cellulose comprises disposing cellulose in an aqueous medium, disposing first and second oxidizing agents in the aqueous medium and oxidizing hydroxyl groups of the cellulose via the first and second oxidizing agents in the presence of a 2,2,6,6-tetramethylpiperidine 1-oxyl radical (TEMPO) catalyst.

Tempo-cellulose structures and related methods

Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.

Inhibitors of oxidized low-density lipoprotein receptor 1 and methods of use thereof

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.

Dehydroleucodine derivatives and uses thereof

The present disclosure relates to triazole derivatives of melampomagnolide B, their synthesis, and their use as anti-cancer compounds.

Triazole derivatives of melampomagnolide B and methods of use thereof

The present invention provides compounds of the formula (I) 

Use of parthenolide derivatives as antileukemic and cytotoxic agents

The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.

Disubstituted triazole analogs

The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML).

Melampomagnolide B dimers

The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.

Combretastatin analogs

Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

Method of treating neuropathic pain

The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML). A compound comprising Formula (1) wherein: Z is independently selected from the group consisting of CH2, O, C(O), and CH, wherein when Z is CH, Z is connected to Y via a double bond and Y is N.

Growing community of inventors

Nicholasville, KY, United States of America

Peter Anthony Crooks